Drugs / BAY1161909
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02138812 | May 2014 → Apr 2017 | — | Bayer | Terminated | No outcome recorded Stop: Business |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY1161909 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02138812 ↗ |
| Known as | CPD 41 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4303241 ↗ |
| Known as | EMPESERTIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4303241 ↗ |
| Known as | MPS1-IN-5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4303241 ↗ |
| Action | Inhibit | “BAY1161909 is a potent and highly selective inhibitor of monopolar spindle 1 (Mps1) kinase activity.” NCT02138812 ↗1“Dual specificity protein kinase TTK inhibitor” CHEMBL4303241 ↗ |
| Modality | Small molecule | — CHEMBL4303241 ↗ |
| Target | TTK | “Dual specificity protein kinase TTK inhibitor” CHEMBL4303241 ↗ |